This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Alliance Remove Business Remove Pharmaceutical Remove Security
article thumbnail

Global Healthcare Industry – M&A and Capital Market Landscape Update

Evalueserve

DECEMBER 6, 2021

The following trends have resulted in an overall improvement in M&A sentiments in the industry vs 2020: Unprecedented levels of alliances in the R&D ecosystem as several major biopharma companies collaborated to effectively leverage their resources to stem innovation. Sponsor deals rebounded exceptionally. Key Market Restraints: .

Capital 98
Capital Globalization Biotech Marketing 98
article thumbnail

Weighing risk and reward with gen AI vendor selection

CIO

JANUARY 3, 2024

Entire businesses have been built on top of OpenAI and its APIs. When assessing vendors, Rich Products looks at their technology, architecture, business value, and pragmatic perspective. The goal, he says, is to understand how AI will benefit Rich’s business overall. “We He’s not the only one. But it’s not exactly a safe bet.

Alliance 803
Alliance Due Diligence Pharmaceutical Technology 803
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 17,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024